Amsterdam-based SME that has hosted PhD secondments in three MSCA doctoral networks on cancer, immunology and AI-driven diagnostics.
Biotecture is a small Amsterdam-based private company that appears in H2020 exclusively as a third-party host for Marie Skłodowska-Curie doctoral training networks, typically offering industry secondments to PhD researchers. Based on the three projects they supported, their practical exposure sits at the crossroads of biomedical R&D and data-driven diagnostics — epigenetics of breast cancer, systems medicine of autoimmune and B-cell disorders, and machine-learning-based brain cancer biosensing. Concretely, they act as an SME-side training environment where academic PhD students get hands-on experience with the business and applied side of biomedical innovation. Note that their public footprint is thin (no website listed, no direct EC funding), so their exact commercial offering is not clearly documented in CORDIS.
All three engagements (EpiPredict, COSMIC, AiPBAND) are MSCA-ITN/ETN networks where they participated as a third party — a role almost exclusively reserved for hosting doctoral secondments.
EpiPredict (breast cancer endocrine therapy resistance) and AiPBAND (brain cancer diagnostic platform) placed them in cancer-focused training consortia.
COSMIC focused on systems medicine approaches to rheumatoid arthritis and B-cell neoplasia.
AiPBAND explicitly combined biosensing, molecular diagnosis, machine learning and cloud computing — the most recent and most applied of their three projects.
The first project (EpiPredict, 2015–2018) had no detailed CORDIS keywords, but its title points to epigenetic regulation in breast cancer. The two later projects starting in 2018 shifted the picture toward systems-medicine framing of immune disorders (COSMIC) and a clearly digital, data-driven direction with AiPBAND — adding biosensing, molecular diagnostics, machine learning, cloud computing and "business" as explicit themes. The trajectory moves from pure biomedical research hosting toward training environments that blend biomedical content with digital diagnostics and commercial translation.
Their most recent engagements lean toward AI-enabled diagnostics and the business side of biomedical research, suggesting they are positioned for doctoral-industry collaborations at the intersection of health data and translational medicine.
They never lead and never participate as a core beneficiary — all three appearances are as a third party in large, Europe-wide doctoral training networks. This is the classic profile of an SME that opens its doors for PhD secondments rather than running its own H2020 work packages. For a partner considering them, this means they are easy to engage for targeted, time-bound training or applied placements, but are not a consortium-building anchor.
Across three MSCA-ITN networks they have been exposed to 48 unique partners in 13 countries, a broad European reach typical of training networks rather than evidence of deep bilateral collaborations. No single country or cluster dominates the picture.
What distinguishes Biotecture in this dataset is its consistent third-party role in doctoral training networks spanning cancer, immunology and AI-driven diagnostics — a Dutch SME that has repeatedly been chosen as an industry training environment by academic consortia. For a partner, the value is access to a small, Amsterdam-based industry host willing to engage with PhD-level biomedical research. It is, however, clearly not positioned as a technology vendor or a consortium leader.
